 |
|
ADVERTISEMENT |
|
Cenegenics is the largest and most experienced Age
Management Medicine Practice in the world with patients from every state
and several countries, 25% of who are physicians and their families.
Through the joint sponsorship of The Cenegenics Medical Institute and
the Foundation for Care Management, Cenegenics provides American Medical
Association PRA Level 4 Classification Tutorial Training in Age
Management Medicine for physicians. Visit our website at www.cenegenics.com.
|
Table Of Contents
Featured Articles
 Nutrigenomics and the Blood Type Diet
Technologies for Aesthetic Medicine
LipoSonix and
UltraShape: New Non-Invasive Alternatives to Liposuction
Ask The Experts
Hormone
Modulation and Replacement - Tom Bader R.Ph
Botox® and Fillers - Dr. Mark Baily, M.D.
Practice
Management - Featured Expert Dr. Alan Mintz
Industry Profile
The Old de Grey Man, He Is What He Chose To Be
Guest Viewpoint
New Frontiers of
Neuroendocrinology: Has America Gone Crazy?
Industry News
Heart Drugs May
Prevent Cancer
Need
Help Cutting Back on Alcohol? Try Kudzu
Drug Meant For
Symptoms Treats a Disease
Scientists Create First Customized Stem Cells
Conference News
Vegas Conference Curriculum Receives Accolades
Achievement in Research & Clinical Excellence Awards
Announced: Presentation to Take Place at Palm Beach Anti-Aging
Conference
Featured Articles
Nutrigenomics and the Blood
Type Diet
Jeff Morris
Rather than keep you hanging on the false promise that
we're going to present anything new or astonishing here about a dietary
breakthrough, we'll get this out of the way right up front: we started
working on this article determined to find some evidence to support the
idea that The Blood Type Diet is a truly remarkable example of how
genetic research can be used to better patients' lives, and that it is
backed up with verifiable studies.
It didn't happen.
Let's start, however, by talking not about the Blood Type Diet, but
about the science of which it is allegedly a part: Nutrigenomics.
Nutritional genomics, or "nutrigenomics," is the study of how different
foods can interact with particular genes to increase the risk of
diseases such as Type 2 diabetes, obesity, heart disease and some
cancers. It is fascinating and promising research, largely begun in 2003
with the establishment of the National Center of Excellence in
Nutritional Genomics at the University of California, Davis, and the
Children's Hospital Oakland Research Institute (CHORI), supported by a
five-year, $6.5 million grant from the National Center on Minority
Health and Health Disparities, a division of the National Institutes of
Health. FULL
ARTICLE
Technologies for Aesthetic
Medicine
LipoSonix and UltraShape: New Non-Invasive Alternatives to
Liposuction
Jeff Morris
New aesthetic medicine technologies that are currently
in the development stage promise to offer non-invasive alternatives to
liposuction. Two companies are competing to bring devices to market
that, while not identical, utilize similar ultrasonic principles to
break up fat cells. Neither is likely to be on the market prior to 2006,
but both offer the prospect of a lower-cost, less painful outpatient
treatment regimen than liposuction.
LipoSonix, Inc., based in Bothell, WA, was founded in 1999 by The
Innovation Factory, an Atlanta technology company "incubator" focused on
developing life science technologies into breakthrough products. The
patented LipoSonix device is called SonoSculpt. LipoSonix chief
executive Jens Quistgaard, who was formerly chief product and strategy
officer at handheld ultrasound maker SonoSite, moved the 3-person
start-up to the Seattle area, one of the leading regions for developers
of ultrasound medical devices, noting, "It doesn't make any sense to do
this type of company in Atlanta; the technology is ultrasound-based so
you have to do it where there are ultrasound people." Quistgaard says
the SonoSculpt procedure will take about an hour in a plastic surgeon's
office, with results that can be seen in about four to six weeks.
Because the SonoSculpt does not involve surgery, Quistgaard said the
device could help grow the market for weight loss procedures. "If you
have something that is safe and non-invasive, people that don't consider
themselves as candidates for surgery would certainly consider this," he
said.
FULL ARTICLE
Ask The Experts
Hormone
Modulation and Replacement - Tom Bader R.Ph
 |
| HORMONE
MODULATION AND REPLACEMENT |
|
|
|
 |
Botox® and
Fillers - Dr. Mark Baily, M.D.
| BOTOX®
AND FILLERS |
|
 |
|
| Dr. Mark Baily,
B.Sc., M.D. |
| Certified Botox®
Instructor |
 |
Cosmetic & Laser
Training Institute
www.cltinstitute.com |
|
|
Practice
Management - Featured Expert Dr. Alan Mintz
Industry Profile
The Old de Grey Man, He Is What
He Chose To Be
Jeff Morris
Aubrey de Grey is driving people crazy, and he likes it that way.
Unfortunately, I'm one of those people.
The 42-year-old computer scientist, self-taught biologist, and chairman
of The Methuselah Foundation, presents a challenge as the subject of a
profile. It's not that information about him is hard to come by, or that
he's squirreled himself away in some obscure corner of the English
countryside refusing to talk to anyone, or that you have to go through a
dozen PR people and be put on a waiting list to get through to him. On
the contrary, I found him to be easy to get hold of, remarkably
forthcoming, and the subject of enough written material -- much of it by
his own hand -- that there isn't a heck of a lot about him still to be
discovered. Which is precisely the problem: The main difficulty is in
trying to find some way to write about him that hasn't already been
done.
I spoke with Dr. de Grey, who received his BA, MA and PhD degrees from
the University of Cambridge, at what must have been around 9 pm
Cambridge time. As is apparently commonplace for him, I didn't really
need to ask him a question; he simply launched into his answer. FULL
ARTICLE
Guest Viewpoint
New Frontiers of
Neuroendocrinology: Has America Gone Crazy?
Ron Shane, Ph.D.
Countless artists, biologists, psychologists,
psychiatrists and philosophers have lucidly explicated that this culture
is becoming mentally pathological. A bevy of mental morbidities are now
actually epidemic in this population. General anxiety syndrome is as
pervasive as having an SUV. Dysthymia is the current omnipresent state
of the American psyche. This culture's fascination with technology may
be the etiological basis of neurophysiological morbidities. "All is not
well," as stated by Shakespeare in the play Hamlet, and this now is the
mood of this society. The sagacious toolmaker is producing objects of
emotional devastation.
Social psychologists suggest that man is extremely adaptive. However,
there is a limit to this species' proclivity to adapt. Neuroscientists
have empirically demonstrated that the human brain is magnificently
hardwired, where trillions of axons have a very precise connection to
specific dendrite. In other words, the human brain is not some arbitrary
blank slate which is as protean as the HO2 molecular. Conversely, these
highly differentiated neuronal tissues have evolved to evoke myriad
species-specific responses. This seemingly adaptive organism does have a
limit to its plasticity before maladaptive responses and
neurophysiological dysregulation become virulently flagrant. FULL
ARTICLE
|
ADVERTISEMENT |
| College Pharmacy is one
of the largest, most comprehensive compounding center in the nation,
producing the highest quality BHRT formulations for Menopause,
Andropause and Anti-Aging, using administration routes and dosages that
optimize patient outcomes. Insurance processing offers the most
competitive pricing and excellence in customer relations. To learn
more about how College Pharmacy can meet your needs visit us at www.collegepharmacy.com.
|
Industry News
Heart Drugs May Prevent
Cancer
Michael Smith
United Press International
Monday, May 16, 2005
ORLANDO, Fla., May 16, 2005 (United Press International via COMTEX) --
New research suggests certain cholesterol-lowering drugs people take to
prevent heart disease also might ward off at least five types of cancer,
but physicians and drugmakers are not ready to make prescribing
recommendations based on the early data.
The studies on the statin drugs, presented at the annual meeting of the
American Society for Clinical Oncology, as well as at a cancer
conference in Chicago on Monday, are encouraging, researchers said.
Statins are sold under the brand names Lescol, Lipitor, Mevacor,
Pravachol, and Zocor.
"Right now, if you need to be prescribed a drug for cholesterol
lowering, many studies suggest you would be better off choosing a statin
for its cancer-preventive effect," said Vikas Khurana, an assistant
professor of medicine at Louisiana State University Health Sciences
Center in Shreveport. Khurana was one of the researchers who presented
data in Orlando. FULL
ARTICLE
Need Help
Cutting Back on Alcohol? Try Kudzu
Alison McCook
Monday, May 16, 2005
NEW YORK (Reuters Health) - Heavy drinkers who tried the herbal extract
kudzu for one week downed fewer drinks than people who received an
inactive placebo treatment, according to new study findings released
Monday.
Study author Dr. Scott E. Lukas of McLean Hospital and Harvard Medical
Center in Massachusetts explained that during the experiment, people
drank their first beer right away, but were less likely to want more
beer if they had taken kudzu the previous week.
"This means that the first beer must have satisfied their initial desire
for alcohol," Lukas suggested.
He said that kudzu may also help deliver blood to the brain, making
people more satisfied with less alcohol. "We can see this in the data
because people took more sips in order to finish each beer, but the sips
were much smaller," Lukas said.
"The net result was that a binge drinker - someone who drinks 4-5 drinks
at one sitting - was reduced to just a few beers," he told Reuters
Health.
FULL
ARTICLE
Drug Meant For Symptoms Treats
a Disease
In startling twist, experimental leukemia drug may be
breakthrough
The Associated Press
Updated: 9:26 a.m. ET May 16, 2005
ORLANDO, Fla. - Doctors were just hoping to treat symptoms when they
gave people with a deadly blood disorder a drug to reduce the need for
transfusions.
To their astonishment, signs of the disease itself disappeared in nearly
half of them.
Specialists said the experimental drug, Revlimid, now looks like a
breakthrough and the first effective treatment for many people with
myelodysplastic syndrome, or MDS, which is even more common than
leukemia.
"It may be, if not eradicating the disease, putting it into what I would
call deep remission," said Dr. David Johnson, a cancer specialist at
Vanderbilt-Ingram Cancer Center who is familiar with but had no role in
the research.
Revlimid "is not yet on the market but almost certainly will be" because
of these findings, he said.
MDS refers to a group of disorders caused by the bone marrow not making
enough healthy, mature blood cells. About 15,000 to 20,000 new cases are
diagnosed each year in the United States, and as many as 50,000
Americans have it now. They usually suffer anemia and fatigue and need
blood transfusions about every eight weeks to stay alive.
"It's a serious problem, it tends to occur in older people, and it's
fatal for most," said Dr. Herman Kattlove, a blood disorder specialist
at the American Cancer Society. FULL
ARTICLE
Scientists Create First
Customized Stem Cells
The Associated Press
Friday, May 20, 2005
WASHINGTON -- South Korean scientists have dramatically sped up the
creation of human embryonic stem cells (search),
growing 11 new batches that for the first time were a genetic match for
injured or sick patients.
It is a major advancement in the quest to grow patients' own replacement
tissue to treat diseases.
The same scientists last year were the first to clone a human embryo.
Now they have improved, by more than tenfold, their efficiency at
culling these master cells, thus making pursuit of therapeutic cloning
more practical.
"I didn't think they would be at this stage for decades, let alone
within a year," said Dr. Gerald Schatten of the University of
Pittsburgh. He acted as an adviser to the Korean lab in analyzing its
data, which was being published Friday in the journal Science.
"This paper will be of major impact," said stem-cell researcher Dr.
Rudolph Jaenisch of the Whitehead Institute for Biomedical
Research (search) in Cambridge, Mass. FULL
ARTICLE
Conference News
Vegas Conference Curriculum
Receives Accolades
The Spring 2005 Integrative Medicine for
Anti-Aging Conference was held May 12-15th at the Las Vegas Hilton,
and based upon attendee comments and evaluations, the conference
curriculum dominated the event. Conference attendees -- an all-time high
of over 90% physicians -- attended four days of lectures focused on
Diseases of Aging, Aesthetics, Hormone Replacement and Integrative
Medicine. Attendee Benito Gallardo, M.D., said, "this conference
provided really good information and has the topics that are applicable
to our growing anti-aging practice." Martha Stark, M.D., a faculty
member at Harvard Medical School, stated, "the level of instruction was
very high and sophisticated. I am very impressed with how generous and
eager the speakers were to offer everything from theory to clinical
applications, so that it all made sense.... I got the 'why's' and the
'how to's'."
There were some pretty clear attendee favorites. Dr. Mark Baily's
lectures on the use of Botox and Fillers were undoubtedly the most
attended events of the conference. The desire for increased practice
revenue outside of managed care by the addition of office-based
aesthetic treatments such as Botox and Soft Tissue Fillers, has driven
attendees to this course repeatedly over the past several years. Dr.
Baily, who conducts hands-on physician training in his Brompton,
Ontario, Canada clinic, provided a clear outline of aesthetic
applications including a live demonstration of injection techniques. FULL
ARTICLE
Achievement in Research &
Clinical Excellence Awards Announced: Presentation to Take Place at
Palm Beach Anti-Aging Conference
In just about every area of medicine, practitioners
whose distinguished accomplishments as clinicians reflect honor on the
discipline, and researchers whose scientific curiosity and diligence
result in new breakthroughs that benefit humanity, are recognized for
their contributions.
Now, a definitive new awards program is being established to acknowledge
outstanding work of physicians and scientists in the growing field of
anti-aging/age management medicine. The Peer-Review Planning Committee
of the Integrative Medicine for Anti-Aging conference will accept
nominations for the first Achievement in Research and Clinical
Excellence Awards.
In announcing the award program, Joseph McWherter, M.D., FACOG, FACS,
chairman of the Committee, noted, "Promotion of healthy aging is an
imperative that is becoming more critical as an ever-increasing
proportion of the worldwide population reaches the later stages of life.
With the healthcare systems of all nations facing this unprecedented
resource challenge, amelioration of the diseases of aging is a vital
strategy for maintaining full functionality."
McWherter continued, "Few medical fields have assembled as impressive a
body of significant progress within a relatively brief timeframe as age
management. It is appropriate that the clinicians who are influencing
lifestyle changes and the researchers taking the knowledge to new levels
be acknowledged for their contributions."
The nomination process is set to begin immediately, and the winners will
be honored at a presentation at the Integrative Medicine for Anti-Aging
Conference at the Palm Beach Convention Center in West Palm Beach, FL,
in October, 2005.
For
the nomination criteria and to make your own selections of potential
award recipients, go to
http://images.antiagingconference.com/files/1103/aagateway/awards.asp
|
|
 |
|
ADVERTISEMENT |
|
|
|
ADVERTISEMENT |
|
|
|
ABOUT THIS NEWSLETTER |
| For information on advertising in
this newsletter, please contact: Rick
Merner |
|
|
|
You are subscribed to this newsletter as <*email*>
To get this newsletter in a different format (Text, AOL or HTML),
or to change your e-mail address, please visit your profile page to change your delivery
preferences.
For questions concerning delivery of this newsletter, please contact our
Customer Service Department at:
US Toll Free: (866) 505-7173
International: (402) 505-7173
or custserv@newsletter.primediabusiness.com
Primedia Business Magazines & Media
9800 Metcalf Avenue
Overland Park, KS 66212
Copyright 2005, PRIMEDIA. All rights reserved. This article is protected
by United States copyright and other intellectual property laws and may
not be reproduced, rewritten, distributed, re-disseminated, transmitted,
displayed, published or broadcast, directly or indirectly, in any medium
without the prior written permission of Primedia Business Magazines &
Media Inc.
|
|
|
